Catheter ablation of atrial arrhythmias in cardiac amyloidosis: Impact on heart failure and mortality.


Journal

PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081

Informations de publication

Date de publication:
2024
Historique:
received: 29 10 2022
accepted: 05 03 2024
medline: 5 4 2024
pubmed: 5 4 2024
entrez: 5 4 2024
Statut: epublish

Résumé

Atrial arrhythmias (AA) commonly affect patients with cardiac amyloidosis (CA) and are a contributing risk factor for the development of heart failure (HF). This study sought to investigate the long-term efficacy and impact of catheter ablation on HF progression in patients with CA and AA. Thirty-one patients with CA and AA undergoing catheter ablation were retrospectively included (transthyretin-ATTR CA 61% and light chain-AL CA 39%). AA subtypes included atrial fibrillation (AFib) in 22 (paroxysmal in 10 and persistent in 12), atrial flutter (AFl) in 17 and atrial tachycardia (AT) in 11 patients. Long-term AA recurrence rates were evaluated along with the impact of sinus rhythm (SR) maintenance on HF and mortality. AA recurrence was observed in 14 patients (45%) at a median of 3.5 months (AFib n = 8, AT n = 6, AFl = 0). Post-cardioversion, medical therapy or catheter ablation, 10 patients (32%) remained in permanent AA. Over a median follow-up of 19 months, all-cause mortality was 39% (n = 12): 3 with end-stage HF, 5 due to late complications of CA, 1 sudden cardiac death, 1 stroke, 1 COVID 19 (and one unknown). With maintenance of SR following catheter ablation, significant reductions in serum creatinine and natriuretic peptide levels were observed with improvements in NYHA class. Two patients required hospitalization for HF in the SR maintenance cohort compared to 5 patients in the AA recurrence cohort (p = 0.1). All 3 patients with deaths secondary to HF had AA recurrence compared to 11 out of the 28 patients whom were long-term survivors or deaths not related to HF (p = 0.04). All-cause mortality was not associated with AA recurrence. This study demonstrates moderate long-term efficacy of SR maintenance with catheter ablation for AA in patients with CA. Improvements in clinical and biological status with positive trends in HF mortality are observed if SR can be maintained.

Sections du résumé

BACKGROUND BACKGROUND
Atrial arrhythmias (AA) commonly affect patients with cardiac amyloidosis (CA) and are a contributing risk factor for the development of heart failure (HF). This study sought to investigate the long-term efficacy and impact of catheter ablation on HF progression in patients with CA and AA.
METHODS METHODS
Thirty-one patients with CA and AA undergoing catheter ablation were retrospectively included (transthyretin-ATTR CA 61% and light chain-AL CA 39%). AA subtypes included atrial fibrillation (AFib) in 22 (paroxysmal in 10 and persistent in 12), atrial flutter (AFl) in 17 and atrial tachycardia (AT) in 11 patients. Long-term AA recurrence rates were evaluated along with the impact of sinus rhythm (SR) maintenance on HF and mortality.
RESULTS RESULTS
AA recurrence was observed in 14 patients (45%) at a median of 3.5 months (AFib n = 8, AT n = 6, AFl = 0). Post-cardioversion, medical therapy or catheter ablation, 10 patients (32%) remained in permanent AA. Over a median follow-up of 19 months, all-cause mortality was 39% (n = 12): 3 with end-stage HF, 5 due to late complications of CA, 1 sudden cardiac death, 1 stroke, 1 COVID 19 (and one unknown). With maintenance of SR following catheter ablation, significant reductions in serum creatinine and natriuretic peptide levels were observed with improvements in NYHA class. Two patients required hospitalization for HF in the SR maintenance cohort compared to 5 patients in the AA recurrence cohort (p = 0.1). All 3 patients with deaths secondary to HF had AA recurrence compared to 11 out of the 28 patients whom were long-term survivors or deaths not related to HF (p = 0.04). All-cause mortality was not associated with AA recurrence.
CONCLUSION CONCLUSIONS
This study demonstrates moderate long-term efficacy of SR maintenance with catheter ablation for AA in patients with CA. Improvements in clinical and biological status with positive trends in HF mortality are observed if SR can be maintained.

Identifiants

pubmed: 38578782
doi: 10.1371/journal.pone.0301753
pii: PONE-D-22-29848
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e0301753

Informations de copyright

Copyright: © 2024 Maury et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Déclaration de conflit d'intérêts

The authors have declared that no competing interests exist.

Auteurs

Philippe Maury (P)

Department of Cardiology, University Hospital Toulouse, Toulouse, France.
I2MC, INSERM UMR 1297, Toulouse, France.

Kevin Sanchis (K)

Department of Cardiology, University Hospital Toulouse, Toulouse, France.

Kamila Djouadi (K)

Department of Cardiology, University Hospital Henri Mondor, Creteil, France.

Eve Cariou (E)

Department of Cardiology, University Hospital Toulouse, Toulouse, France.

Hubert Delasnerie (H)

Department of Cardiology, University Hospital Toulouse, Toulouse, France.

Serge Boveda (S)

Clinique Pasteur, Toulouse, France.

Pauline Fournier (P)

Department of Cardiology, University Hospital Toulouse, Toulouse, France.

Romain Itier (R)

Department of Cardiology, University Hospital Toulouse, Toulouse, France.

Pierre Mondoly (P)

Department of Cardiology, University Hospital Toulouse, Toulouse, France.

Quentin Voglimacci-Stephanopoli (Q)

Department of Cardiology, University Hospital Toulouse, Toulouse, France.

Maxime Beneyto (M)

Department of Cardiology, University Hospital Toulouse, Toulouse, France.

Tarvinder S Dhanjal (TS)

Department of Cardiology, University of Warwick, Coventry, United Kingdom.

Anne Rollin (A)

Department of Cardiology, University Hospital Toulouse, Toulouse, France.

Thibaud Damy (T)

Department of Cardiology, University Hospital Henri Mondor, Creteil, France.

Olivier Lairez (O)

Department of Cardiology, University Hospital Toulouse, Toulouse, France.

Nicolas Lellouche (N)

Department of Cardiology, University Hospital Henri Mondor, Creteil, France.

Classifications MeSH